Core Points - The company aims to enhance the compensation management for its directors and senior management to stabilize the core management team and improve operational efficiency [1] - The compensation system is designed to align with the company's goals and performance, ensuring that remuneration reflects the value of each position [1][2] - The board of directors is responsible for reviewing the compensation of senior management, while the shareholders' meeting reviews the compensation of directors [2] Compensation Management Structure - The Compensation and Assessment Committee of the board is authorized to manage and assess the compensation plans for directors and senior management [2] - The Human Resources and Administration Department will assist the Compensation and Assessment Committee in implementing the compensation plans [2] Compensation Standards and Adjustments - The compensation system will adapt to the company's operational changes and align with its strategic goals [2] - Adjustments to the compensation of directors and senior management will be based on industry salary increases, inflation, company profitability, organizational changes, and specific roles [2][3] Compensation Distribution - The distribution of salaries and allowances for directors and senior management will follow the company's compensation management regulations [2] - Compensation for departing directors and senior management will be calculated based on their actual tenure and performance [2] Additional Provisions - Any matters not covered by this system will adhere to relevant national laws and regulations, as well as the company's articles of association [4] - The board of directors is responsible for interpreting this system, which will take effect upon approval by the shareholders' meeting [5]

Group 1 - The company Jinlitai (300225) has received a notice of investigation from the China Securities Regulatory Commission (CSRC) [1] - The investigation is due to the company's failure to disclose the 2024 annual report within the statutory deadline [1] - The CSRC has decided to initiate the investigation on May 6, 2025, based on the Securities Law and the Administrative Penalty Law of the People's Republic of China [1]

Financial Performance - The company reported a basic earnings per share of 0.0100 yuan for 2024, a significant increase of 112.5% compared to a loss of 0.0800 yuan in 2023 [1] - The total revenue for 2024 was 3.5 billion yuan, reflecting a decrease of 30% from 5 billion yuan in 2023 [1] - The net profit for 2024 was 0.04 billion yuan, a turnaround from a loss of 0.35 billion yuan in 2023, marking an increase of 111.43% [1] - The return on equity improved to 0.35% in 2024 from -2.74% in 2023, indicating a recovery in profitability [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 20,272.94 million shares, accounting for 46.74% of the circulating shares, with an increase of 1.8051 million shares compared to the previous period [1] - The largest shareholder, Chongqing Life Science and New Materials Industry Group Co., Ltd., holds 17,580.90 million shares, representing 40.55% of the total share capital, with no change in holdings [2] - New entrants among the top shareholders include Ai Wanfen and Liu Yuanwang, holding 273.02 thousand shares and 156.30 thousand shares respectively [2] Dividend Distribution - The company announced a dividend distribution plan of 0.15 yuan per share (including tax) [3]